Irvine, Calif., Oct. 27, 2020 - Treating cancer without debilitating side effects has long been the holy grail of oncologists, and researchers at the University of California, Irvine and Switzerland's Lausanne University Hospital/University of Luassanne (CHUV/UNIL) may have found it.
Charles Limoli, professor of radiation oncology at UCI, and Marie-Catherine Vozenin, associate professor of radiation oncology at CHUV/UNIL, used an ultra-high dose rate of radiation therapy to eliminate brain tumors in mice, bypassing key side effects usually caused by cranial irradiation. Their findings are published in Clinical Cancer Research.
"It's not unreasonable to expect that in 10 years, this may become a widespread option for radiotherapy patients worldwide," Limoli said.
Traditional radiation therapy exposes a tumor and nearby normal tissue to radiation for several minutes at a time, but FLASH radiation therapy (FLASH-RT) allows delivery of the same dose in only tenths of seconds. The speed eliminates many of the toxicities that normally plague cancer survivors long after radiation treatments, significantly decreasing side effects such as inflammation and impairments to cognition.
As in traditional radiation therapy, the researchers fractionated the dose - divided the total over several sessions. Using FLASH-RT, they found that the same total dose of radiation delivered at quicker dose rates removed brain tumors just as effectively as the traditional method.
"This is very important, since fractionation is the standard in the clinic and the easiest way to transfer FLASH-RT at the clinical level," said principal investigator Vozenin, an adjunct professor at UCI.
Though this work focused on the brain, FLASH-RT has also been used to treat lung, skin and intestinal cancers, while still preventing many radiation-induced complications. These additional studies have been successful across several types of animals, including fish, mice, pigs, cats and one human subject.
"It seems that this treatment is going to be universally beneficial for most cancer types," Limoli said.
Now that researchers have verified that the method works, groups around the world are developing machines that would make FLASH technology available in clinics. One device is awaiting approval in the U.S. and Europe, and Vozenin plans to use it in two clinical trials at CHUV early next year.
Meanwhile, she and Limoli are investigating the mechanisms behind FLASH-RT's beneficial effects to better understand how the technology works.
Said Limoli: "In the last 30 or 40 years, I'd say, there's been nothing in the field of radiation sciences as exciting as this."
About the University of California, Irvine: Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 222 degree programs. It's located in one of the world's safest and most economically vibrant communities and is Orange County's second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit http://www.uci.edu.
Media access: Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UCI faculty and experts, subject to availability and university approval. For more UCI news, visit news.uci.edu. Additional resources for journalists may be found at communications.uci.edu/for-journalists.
Clinical Cancer Research